Luis Hernandez

About Luis Hernandez

Enterprise Evidence Strategy Leader translating science into decisions that determine patient access, adoption, and enterprise value across U.S. and global oncology portfolios and pipeline assets, with prior experience across specialty care. I lead enterprise evidence strategy across U.S. and global oncology portfolios, establishing the operating model that aligns clinical development, real-world evidence, and HEOR to shape development decisions, remove access barriers, and drive adoption across markets, grounded in more than two decades of leadership across oncology and specialty care. At Takeda Oncology, I established Global Health Economics as an enterprise evidence function and transformed U.S. HEOR into a market-facing organization aligned with payer, health system, and clinical decision needs. This model connects global evidence strategy with U.S. access and adoption, delivering formulary gains, removal of access restrictions, and real-world evidence supporting provider and health system uptake across a multi-asset oncology portfolio. I set the direction for defining evidence requirements early, before pivotal trial design, ensuring development programs generate the evidence needed for regulatory, HTA, payer, guideline, and clinical decision-making. I lead integrated evidence strategy across the lifecycle so that by launch, the conditions for access and adoption are already in place across markets. I build and lead multidisciplinary organizations across health economics, real-world evidence, and epidemiology, aligning R&D, medical affairs, and market access around shared external decision points. I have also advanced modernization of evidence generation through AI-enabled synthesis, accelerated economic modeling, and scalable real-world data partnerships across U.S. and global platforms.All opinions and views are my own.

Experience

1. Head, Global Health Economics and Head, Us Heor

   Takeda Oncology

   Jun 2023 — Present · Cambridge, MA, US

   Lead enterprise evidence strategy across U.S. and global oncology portfolio and pipeline assets, shaping development, access, and adoption decisions across markets, spanning multiple therapies and 20+ indications- Built Global Health Economics into an enterprise evidence function aligning development strategy, evidence generation, and payer and HTA requirements across a multi-asset oncology portfolio- Transformed U.S. HEOR into a market-facing organization delivering formulary gains and removal of access restrictions across national and regional payers, supported by real-world evidence adoption across health systems- Set enterprise evidence strategy across portfolio and pipeline assets, ensuring development programs generate evidence required for regulatory, value assessment, and clinical adoption decisions across multiple late-stage and launch assets- Established enterprise evidence governance and investment discipline, aligning evidence strategy to portfolio priorities and improving decision-making, speed, and efficiency across multiple indications and programs- Shaped evidence strategy in response to evolving U.S. policy and value assessment dynamics, including IRA-driven pricing and access considerations impacting oncology portfolios- Established U.S. value communication capability, enabling ICER readiness and proactive payer engagement (FDAMA 114)

Education

• Universidad de Los Andes

  MSc and BSc, Industrial Engineering (Operations Research and Statistics)

• University of Groningen

  Doctor of Philosophy - PhD, Health Economics

• Tufts University

  Master of Public Health - MPH, Epidemiology and Biostatistics

• MIT Sloan School of Management

  Organizational Leadership

Skills

• Health Economics
• Literature Reviews
• Mathematical Modeling
• Data Analysis
• Epidemiology
• Decision Modeling
• System Dynamics
• Project Management
• Simulations
• Discrete Event Simulation
• Operations Research
• Statistics
• Team Management
• Sas
• Management
• Statistical Modeling
• Pharmacoeconomics
• Predictive Modeling
• R
• Pharmaceutical Industry
• Health Technology Assessment (Hta)
• Optimization
• Director Level
• Decision Analysis
• Drug Development